One of the things you need to know about cancer treatment is that every case of cancer actually develops to some extent. is that it is original. Even if the mutations that cause cancer and the regions where these mutations occur are known, differences in people’s genetic structures can cause them to respond differently to each drug. A new study offers hope for patients in this regard.

A new development developed by scientists artificial intelligence algorithmhas been successful in creating complex chemical models from the early stages of drug development. Artificial intelligence can optimize this process, which under normal circumstances requires thousands of experiments.

32 potential drugs have been developed

The main feature of the drugs developed using the artificial intelligence algorithm POLYGON is molecules with multiple targets It is shown as being able to recognize. In other words, these drugs have the potential to simultaneously destroy cancerous structures that have arisen or spread in different places.

Lead author of the study Trey Idekerabout the issue “It takes many years and millions of dollars to find and develop a new drug, especially if we are talking about a drug with more than one target. The few rare multi-target drugs we have were discovered largely by chance, but this new technology ignore coincidences to take off and could help usher in the next generation of precision medicine.” He uses the expressions.

Billions of bioactive molecules chemical properties and trained with data on their interactions with target proteins, AI can thus produce original chemical formulas. For this it is sufficient to simply say what the interaction will be like.

As a result of this research, POLYGONMEK1 and mTOR managed to find 32 cancer drugs that showed excellent interaction with cellular signaling proteins. If both structures are suppressed, cancer cells die. It seems that artificial intelligence is preparing for a revolution in this area too.

Research Nature communicationIt was published in .